Protein differences in early-onset, late-onset, and inherited Alzheimer's
A Proteomic Comparison of Sporadic Early-Onset, Late-Onset, and Autosomal Dominant Alzheimer's Disease
This project compares protein changes in people with early-onset, late-onset, and inherited Alzheimer’s to find biological differences that could explain symptoms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11193458 on NIH RePORTER |
What this research studies
Researchers will compare proteins found in brain tissue and biofluids from people with sporadic early-onset Alzheimer’s, typical late-onset Alzheimer’s, and autosomal dominant (inherited) Alzheimer’s. They will use advanced proteomics methods to map changes in pathways such as mitochondrial function, protein quality control, immune complement, and RNA-associated proteins. The team will look for shared and distinct protein patterns across these Alzheimer’s types and seek fluid biomarkers that reflect brain changes. Results will be used to better understand why early-onset cases can present differently and progress faster than late-onset cases.
Who could benefit from this research
Good fit: Ideal candidates are people diagnosed with early-onset Alzheimer’s (before age 65), people with typical late-onset Alzheimer’s, or individuals from families with known autosomal dominant Alzheimer’s mutations who can provide clinical information or biological samples.
Not a fit: People without Alzheimer’s or those whose cognitive problems are due to non‑Alzheimer’s causes may not directly benefit from this specific project.
Why it matters
Potential benefit: If successful, this work could identify biomarkers and biological pathways that help diagnose Alzheimer’s subtypes earlier or point to targeted treatment approaches.
How similar studies have performed: Previous proteomic studies in late-onset Alzheimer’s have revealed many disease-related protein changes, but applying this approach specifically to sporadic early-onset Alzheimer’s is relatively new.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Johnson, Erik C.b. — Emory University
- Study coordinator: Johnson, Erik C.b.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.